Introduction
Cell-cycle checkpoint kinase 2 (CHEK2 [MIM 604373] ) is a tumor suppressor gene widely researched as a strong candidate gene for breast cancer susceptibility (Iniesta et al. 2010; Vahteristo et al. 2002 ; CHEK2 Breast Cancer Case-control Consortium CHEK2*1100delC and susceptibility to breast cancer 2004; Mateus Pereira et al. 2004; Offit et al. 2003; Zhang et al. 2008; Rashid et al. 2005; Kleibl et al. 2005; Cybulski et al. 2007; Friedrichsen et al. 2004; Bernstein et al. 2006; Sodha et al. 2002; McInerney et al. 2009; Dufault et al. 2004; Einarsdottir et al. 2006; Weischer et al. 2007; Baeyens et al. 2005; Fletcher et al. 2009 ). The CHEK2 gene has been shown to play a major role in deoxyribonucleic acid (DNA) repair, apoptosis and cell cycle regulation. Indeed, in response to DNA damage, the ATM/CHEK2/p53 pathway is activated. The ATM (Ataxia Telangiectasia Mutated) phosphorylates CHEK2, which in turn phosphorylates p53 leading to cell cycle arrest and apoptosis (Iniesta et al. 2010 ). In addition, CHEK2 protein regulates BRCA1 in response to DNA damage (Oldenburg et al. 2007 ).
The CHEK2 1100delC protein truncating variant is situated in exon 10 of the functional gene on chromosome 22q. This variant is caused by the deletion of a single cytosine at position 1100 resulting in the introduction of a stop codon after amino acid 380, inducing a loss of activity of the CHEK2 kinase (Iniesta et al. 2010) .
The CHEK2 1100delC variant was found in women suffering from breast cancer with familial Li-Fraumeni syndrome (Bell et al. 1999) . In 2004, CHEK2-Breast Cancer Consortium did a collaborative analysis with 10 studies from 5 western countries, which involved 10 860 breast cancer cases and 9 065 controls (CHEK2 Breast Cancer Case-control Consortium CHEK2*1100delC and susceptibility to breast cancer 2004). The Consortium found the frequency of CHEK2 1100delC to be 1.9% and 0.7% in cases and controls respectively, and confirmed that this gene variant could potentially increase the risk of breast cancer. The CHEK2 1100delC variant has been reported to be a low-penetrance breast cancer susceptibility allele (Vahteristo et al. 2002 ; CHEK2 Breast Cancer Case-control Consortium CHEK2*1100delC and susceptibility to breast cancer 2004; Oldenburg et al. 2003; Kuusisto Kirsi et al. 2011) . It results in an approximately two-fold risk of breast cancer in women and a ten-fold risk in men (van der Groep et al. 2011) . It has been detected in 5% of breast cancer patients from non-BRCA1 and BRCA2 families (Vahteristo et al. 2002; MeijersHeijboer et al. 2002) . The frequency of CHEK2 1100delC allele varies among different populations. Indeed, high mutation rates are seen in Northern and Eastern European countries (Vahteristo et al. 2002 ; CHEK2 Breast Cancer Case-control Consortium CHEK2*1100delC and susceptibility to breast cancer 2004; Meijers-Heijboer et al. 2002) although its frequency is much lower in North America (Mateus Pereira et al. 2004; Offit et al. 2003) , whereas the mutation does not seem to be a triggering factor to breast cancer in Poland (Kwiatkowska et al. 2006; Cybulski et al. 2004 ) and some multiple-case breast cancer families from Australia (Jekimovs et al. 2005) . Likewise, the frequency of CHEK2 1100delC seems to be very low in Southern Europe, Italy (Caligo et al. 2004) , Spain (Osorio et al. 2004; Bellosillo et al. 2005 ) and rare in Brazil .
Moreover, another quantitative synthesis was done by Weischer et al. (Weischer et al. 2007) . Combined with 16 studies, it showed that CHEK2 1100delC heterozygotes rate was 3-to 5-fold higher in the breast cancer group than the control group. However, this widely discussed variant of CHEK2 -which seemed clearly associated with the predominance of breast cancer in western countries -was rarely detected in Asian populations, such as the Chinese (Song et al. 2006) , Koreans (Choi et al. 2008) , Japanese (Bell et al. 2007 ), Singaporeans (Lee & Ang 2008) , Malaysians (Thirthagiri et al. 2009 ) and South Indians (Rajkumar et al. 2003) .
In Morocco, according to the Greater Casablanca Cancer Registry, breast cancer seems to be the first female cancer with a standardized incidence of 36.4 per 100,000 women for an average age of 49.5 years (Bouchbika et al. 2013) . Although this incidence appears higher compared to the other Maghreb countries (Hamdi Cherif et al. 2010; Ben Abdallah et al. 2009; El Mistiri et al. 2010) , it remains low compared to developed countries (Marrett et al. 2008; Botha et al. 2003; Jemal et al. 2011 ). In the greater area of Casablanca, 57 % of the cases were under 50 years of age (Bouchbika et al. 2013 ) and 7% of cases registered at the city of Rabat are younger than 35 years (Tazi et al. 2013 ).
In addition, Morocco is a country of northwestern Africa composed predominantly of Berber and Arab Individuals affected with breast Deceased Figure 1 Pedigree corresponding to one of the families included in the present study of CHEK2 1100delC mutation in hereditary breast cancer. The index case is indicated with an arrow. ethnic groups. The contribution of these ethnic groups to the genetic diversity of Moroccan population is evident. Therefore, it is crucial to improve our understanding, both on the subject of genetic susceptibilities and environmental risk factors. In the present study, we examined DNA from Moroccan patients who have been screened and found not to carry BRCA1/2 mutations. The purpose of the study was to determine the frequency of CHEK2 1100delC mutation and the implication of CHEK2 as a breast cancer susceptibility gene in the Moroccan population. Data were collected from medical records and clinicopathological reports. The group of sporadic cases (n = 75) presented a mean age of 36.9 years with an age range of 23-59 years. The group of familial breast and/or ovarian cases (n = 59) presented a mean age of 44.8 years with an age range of 25-67 years, and included women with specific family-history criteria ( Figure 1 ):
Materials and methods

Subjects
Three or more first or second degree relatives with breast cancer diagnosed in the same familial branch, at any age Two first degree relatives with breast cancer, with at least one early onset breast cancer case (≤40 years) or male breast cancer case or ovarian cancer case.
The control group included a total of 114 matched healthy women with no personal history of cancer diseases selected from DNA bank volunteers of the Genetics and Molecular Pathology Laboratory with a median age of 36.4 years and an age range of 20-77 years.
The study was approved by our institutional ethics committee and written informed consent for genetic testing was obtained from all subjects.
DNA isolation and PCR amplification
Genomic DNA was extracted from peripheral blood leukocytes using the salting out method (Miller et al. 1988) . Genomic DNA was dissolved in TE (10 mM Tris-HCl and 0.1 mM EDTA, pH 8.0), confirmed by agarose gel electrophoresis and then quantified using the Nanovue TM Plus spectrophotometer.
ASO-PCR analysis was performed to determine the 1100delC mutation of CHEK2 gene, as described previously (Rashid et al. 2005) .The CHEK2 1100delC mutation genotyping was performed with forward primer CHEK2ex10f (5′-GCAAAATTAAATGTCCTAACTTGC-3′) in combination with previously described reverse primers CHEK2ex10r andCHEK2delCr primers (Cybulski et al. 2004) .
CHEK2 gene was amplified in a final volume of 25 μl containing: 10× reaction buffer, 25 mM MgCl 2 , 5 mM dNTPs, 5 μM primers, 500 U HotStarTaq DNA polymerase and 150 ng genomic DNA. Touchdown PCR 
Results
A total of 134 Moroccan subjects were selected for our study. General characteristic of the subjects including distribution of tumor characteristic such as histological grade and location of cancer were obtained from patients' medical records and listed in Table 1 . In total, 134 breast cancer cases and 114 controls were successfully screened for the 1100delC variant of the CHEK2 gene using the ASO-PCR technique. None of the 134 Moroccan breast cancer patients carried the CHEK2 1100delC mutation. Moreover among the 134 cases, 40 patients had been screened for BRCA1 and BRCA2 mutations (Tazzite et al. 2012) . Thus, in the 30 patients who were non-BRCA mutation carriers, the analysis of 1100delC mutation was also found negative.
This finding suggests that this mutation is probably not present or is present at an extremely low frequency in Moroccan population.
Discussion
In our present molecular study, we evaluated the involvement of the low-penetrance susceptibility 1100delC allelic variant in the CHEK2 gene in the Moroccan population. For this purpose, we performed a screening of this mutation in 134 Moroccan breast cancer patients and 114 healthy controls. Our results have shown that none of the 248 analyzed samples carried the CHEK2 1100delC mutation, suggesting that the frequency of this mutation is extremely low (or not present) in the Moroccan population.
On the other hand, our results are in line with some previous findings showing that there was no association between CHEK2 1100delC mutation and risk for Breast Cancer Caligo et al. 2004; Osorio et al. 2004; Bellosillo et al. 2005; Rajkumar et al. 2003; Sodha et al. 2007; Gonzalez-Hormazabal et al. 2008) (Table 2 ). Nonetheless, it should be noted that in Northern and Eastern European (Vahteristo et al. 2002 ; CHEK2 Breast Cancer Case-control Consortium CHEK2*1100-delC and susceptibility to breast cancer 2004; MeijersHeijboer et al. 2002 ) CHEK2 1100delC mutation is associated with an increased risk of Breast Cancer (on the basis of age at diagnosis and family history of breast cancer).
A rational explanation for these discrepancies may be due to ethnic or geographic variations. As reported in several studies, it is evident that the contribution of CHEK2 1100delC mutation to the burden of cancer varies according to the ethnic group, and from country to country (Antoni et al. 2007; Gonzalez-Hormazabal et al. 2008; Martınez-Bouzas et al. 2007) (Table 2 ). For instance, CHEK2 1100delC mutation was frequently observed in some Western and Northern Europe (CHEK2 Breast Cancer Case-control Consortium CHEK2*1100delC and susceptibility to breast cancer 2004), but it was very rare in the Central Europe (Kleibl et al. 2005; Kwiatkowska et al. 2006) , Southern Europe (Italy and Spain) (Caligo et al. 2004; Osorio et al. 2004) and Australia (Jekimovs et al. 2005) . In Basque Country, Martinez-Bouzas et al. reported the 1100delC mutation in 0.93% of the cases with breast cancer, and in none of the control populations. Therefore, the authors raise the hypothesis of the existence of a 1100delC frequency gradient from the North-West to the South-East of Europe, caused by an ancestral common origin in the Northern Europe (Osorio et al. 2004; Gonzalez-Hormazabal et al. 2008; Martınez-Bouzas et al. 2007 ). Likewise, this variant is very low in North America (CHEK2 Breast Cancer Case-control Consortium CHEK2* 1100delC and susceptibility to breast cancer 2004; Offit et al. 2003) , and rare in Brazil . The CHEK2 1100delc mutation is not present in Chilean families with familial breast (Gonzalez-Hormazabal et al. 2008) , and it was rarely detected in Asian populations, such as the Chinese (Song et al. 2006; Chen et al. 2008) , Koreans (Choi et al. 2008) , Japanese ), (Thirthagiri et al. 2009 ), South Indians (Rajkumar et al. 2003) , and Philippines . Antoniou et al. (2002) suggested that susceptibility to breast cancer in non-carriers of BRCA1 and BRCA2 mutations may be mainly due to a "polygenic" model, with a large number of susceptibility alleles, each conferring a small increase in risk. Further evaluation of these interactions will be required to identify and analyze other susceptibility genes. Moreover, Martınez-Bouzas et al. (2007) detected a 0,93% prevalence among 214 Basque Country non BRCA1/2 patients and Gutiérrez-Enríquez et al. (2008)) reported 0,3% frequency in 331 non BRCA1/2 families from Basque Country and Catalonia. On the other hand, Zhang et al. (2008) found no CHEK2 mutation in 307 White women with breast cancer and a BRCA mutation. It is unlikely that women with a BRCA mutation will be found to harbor a CHEK2 mutation.
However, it is possible that other CHEK2 variants will confer susceptibility to breast cancer in other countries. Therefore, many studies screened the full coding sequence of CHEK2. For example, a splice-site mutation in CHEK2 IVS2 + G > A has been found to be associated with breast cancer susceptibility in Poland (Cybulski et al. 2007) , and the S428F allele of the CHEK2 gene increases breast cancer risk in Ashkenazi Jewish women (Shaag et al. 2005 ). Likewise, several previous studies have suggested that CHEK2 I157T variant may contribute to inherited breast cancer predisposition (Cybulski et al. 2007; Kilpivaara et al. 2004; Bogdanova et al. 2005) .
A limitation of our study was the reliance on family members' reports of cancer in their relatives. Secondly, the sample size was limited and it is important to confirm our findings in a larger study. Thirdly, this study only focused on single gene without taking into consideration SNP-SNP and gene-gene interactions, or the possibility of linkage disequilibrium between polymorphisms, which may affect individual susceptibility to breast cancer.
Conclusion
Since its discovery as a BC susceptibility allele, the occurrence of CHEK2 1100delC mutation depends on the geographical area and/or ethnical characteristics of populations (CHEK2 Breast Cancer Case-control Consortium CHEK2* 1100delC and susceptibility to breast cancer 2004). Thus, the absence or rarity of the CHEK2*1100delC heterozygosity among patients with breast cancer in our population underlines the importance of considering ethnic background before offering a genetic test. Further studies need to expand and elaborate on the putative contribution of this variant in the Moroccan population.
